Response Letter: C-Reactive Protein-Albumin-Lymphocyte (CALLY) Index as a Novel Biomarker of Prognosis in Patients With Cardiovascular Disease

Abstract

Get full access to this article

View all access options for this article.

References

Ren

L-Y

H-L

. Comment on “Association between the C-reactive protein-albumin-lymphocyte (CALLY) index and length of hospital stay in patients with heart failure.” Angiology. 2026;77:782-783.

Candemir

Kızıltunç

Yamak

BA.

Association between the C-reactive protein-albumin-lymphocyte (CALLY) index and length of hospital stay in patients with heart failure. Angiology. 2026;77:772-778.

Luo

C-reactive protein-albumin-lymphocyte index as a feasible nutrition-immunity-inflammation marker of the outcome of all-cause and cardiovascular mortality in elderly. Clin Nutr ESPEN. 2024;63:346-353.

Pan

Deng

, et al. Association between the C-reactive protein-albumin-lymphocyte (CALLY) index and adverse clinical outcomes in CAD patients after PCI: findings of a real-world study. Rev Cardiovasc Med. 2024;25(4):111.

Luo

, et al. Prognostic significance of C-reactive protein-albumin-lymphocyte (CALLY) index after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Int Immunopharmacol. 2024;141:112860.